Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study.

Organ transplantation is associated with an early bone loss that subsequently increases the risk of osteopenia and bone fractures. It is not known whether bone loss continues in long-term survivors, but persistent bone demineralization could further jeopardize an already diminished bone mass. To better define long-term bone status of kidney transplant recipients (KTR), we conducted cross-sectional and longitudinal evaluations of bone mineral density (BMD) in 70 KTR with a mean posttransplantation time of 8.1 years. BMD was determined by dual-energy X-ray absorptiometry and was repeated in 55 of the patients after a mean follow-up period of 22 +/- 5 months. Lumbar and femoral osteopenia, defined as a BMD lower than 2 standard deviations from mean value of sex- and age-matched controls, was present in 28.6% and 10.5% of patients, respectively. There was a significant negative correlation between cumulative prednisone dose and adjusted lumbar as well as femoral BMD (R = 0.45, P < 0.001 and R = 0.29, P < 0.05, respectively). Five patients had a vertebral BMD below a fracture threshold of 0.777 g/cm2. Vertebral fractures (VF) were found in four men and were associated with higher prednisone dosage (P < 0.05), larger cumulative prednisone dose (P < 0.05), and significantly lower BMD values. According to World Health Organization recent criteria for women, prevalences of lumbar and femoral osteopenia and lumbar and femoral osteoporosis in female patients reach 75%, 65%, 33%, and 10%, respectively. The longitudinal part of the study showed a persistent pathological lumbar demineralization process. Over the study period, BMD, expressed as a percentage of that of controls, decreased from 89 +/- 14% to 86 +/- 14% (P < 0.001). Annual change of bone mass was -1.7 +/- 2.8% per year. Accelerated vertebral bone loss (defined as a decrease of BMD, expressed as a percentage of that of controls, of more than 1% per year) was present in 56% of patients and was associated with higher prednisone dosage (P < 0.01). In conclusion, although VF are relatively infrequent in long-term survivors of renal transplantation, osteopenia is a frequent finding, and a substantial proportion of women present lumbar osteoporosis. An ongoing demineralization process of the spine is also demonstrated and probably contributes to long-term spinal osteoporosis incidence. Prednisone dosage remains the most constantly isolated risk factor.

[1]  S. Epstein,et al.  Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. , 1988, Endocrinology.

[2]  William N. Kelley,et al.  Textbook of rheumatology , 1985 .

[3]  M. de Vernejoul,et al.  Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. , 1991, Endocrinology.

[4]  P. Schollmeyer,et al.  Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. , 1994, Transplantation.

[5]  P. Schollmeyer,et al.  Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. , 1995, Transplantation.

[6]  E. Dickson,et al.  Bone disease in liver transplant recipients: incidence, timing, and risk factors. , 1991, Transplantation proceedings.

[7]  S. Epstein,et al.  The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. , 1994, Transplantation.

[8]  R. Recker,et al.  Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. , 1977, Annals of internal medicine.

[9]  D. Hricik,et al.  FACTORS INFLUENCING VERTEBRAL BONE DENSITY AFTER RENAL TRANSPLANTATION , 1994, Transplantation.

[10]  P. Delmas,et al.  Bone loss after orthotopic liver transplantation. , 1994, The American journal of medicine.

[11]  R. Lindsay,et al.  LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN EVIDENCE FOR AN INCREASED BONE MASS AFTER DELAYED ONSET OF ŒSTROGEN TREATMENT , 1976, The Lancet.

[12]  E. Shane,et al.  Osteoporosis after cardiac transplantation. , 1993, The American journal of medicine.

[13]  J. Casez,et al.  Changes in bone mass early after kidney transplantation , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[15]  S. Epstein,et al.  Perspectives: Posttransplantation bone disease , 1992 .

[16]  B. Julian,et al.  Rapid loss of vertebral mineral density after renal transplantation. , 1991, The New England journal of medicine.

[17]  K.,et al.  Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. , 1981, The Journal of clinical investigation.

[18]  Y. Ye,et al.  Loss of vertebral bone density in heart transplant patients. , 1991, Transplantation proceedings.

[19]  C. Cooper,et al.  Fortnightly Review: Bone densitometry in clinical practice , 1995, BMJ.

[20]  J. Cunningham,et al.  Loss of regional bone mineral density in the first 12 months following renal transplantation. , 1994, Nephron.

[21]  J. Cunningham,et al.  Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. , 1992, Mineral and electrolyte metabolism.

[22]  D. Mancini,et al.  Osteoporosis and bone morbidity in cardiac transplant recipients. , 1994, The American journal of medicine.

[23]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.

[24]  C. Gips,et al.  Bone disease after orthotopic liver transplantation. , 1988, Journal of hepatology.